Qaytarish

Gepatit A ga qarshi antitana, IgM

Kod:17010|CPT:86709|LOINC:13950-1

Sinonimlar
Антитела класса IgM к вирусу гепатита А.Anti-HAV, IgMAntibodies to Hepatitis A Virus, IgMAntibody to Hepatitis A Virus, IgMHAVAb, IgMHepatitis A Antibody, IgMHepatitis A virus IgM antibodiesViral Hepatitis A Antibody
KabiGepatit A ga qarshi antitana, IgM

Tahlil ma'lumotlari

Tadqiqot usuli

  • Immunokimyoluminometrik analiz (ICMA)
  • Elektrokimyoluminessent immunoanaliz (ECLIA)

Kutilayotgan natija topshirish vaqti

1 kun

Maxsus tayyorlik

  • Inform the laboratory about high-dose biotin use (vitamin B7/B8, vitamin H, coenzyme R) and stop it for at least 72 hours before collection.
  • Do not smoke during the 30 minutes prior to specimen collection.

Qanday foydalanish

Gepatit A ga qarshi antitana, IgM (anti-HAV IgM; HAVAb, IgM) HAVga xos IgMni sifatli aniqlash orqali o'tkir yoki yaqinda yuz bergan gepatit A virusi infeksiyasi diagnostikasiga yordam berish uchun qo'llaniladi. U o'tkir gepatitga xos klinik belgilar yoki laborator topilmalar mavjud bo'lgan bemorlarda yoki gumon qilingan ta'sirlanishdan so'ng qo'llash uchun mos bo'lib, rutin populyatsion skrining uchun mo'ljallanmagan. Testni mos simptomlari yoki ta'sirlanish tarixi bo'lgan bemorlar bilan cheklash soxta ijobiy natijalarni kamaytirishga yordam beradi. IgM anti-HAV odatda infeksiyadan 2–3 hafta o'tgach aniqlanadi va bir necha oy (2–6 oy) davom etadi. Aksincha, IgG anti-HAV keyinroq rivojlanadi va o'tmishda bo'lib o'tgan infeksiya yoki immunitetni ko'rsatadi.

Cheklovlar

Gepatit A asosan fekal–oral yo'l orqali ifloslangan oziq-ovqat yoki suv bilan, yoki infeksiyalangan shaxs bilan yaqin kontakt orqali yuqadi. Natijada yuzaga keladigan jigar yallig'lanishi bilirubin almashinuvini va azotli chiqindilarni chiqarilishini buzadi, ko'pincha zardobdagi bilirubinning oshishi va jigar fermentlari faolligining ko'tarilishi bilan namoyon bo'ladi. HAVga qarshi IgM antitanalar odatda infeksiyadan taxminan 2–3 hafta o'tgach aniqlanadi va 2–6 oy davomida saqlanadi, IgG anti-HAV esa keyinroq paydo bo'ladi va odatda umr bo'yi saqlanadi. Ushbu analiz qon yoki plazma donorlarini skrining qilish uchun tasdiqlanmagan yoki ma'qullanmagan. Ishlash ko'rsatkichlari immuniteti buzilgan yoki immunosupressiya qilingan bemorlar, kindik qoni, 2 yoshdan kichik bemorlar yoki kadaver namunalari uchun o'rnatilmagan.

O'lchov birligiqualitative
Referens oraliq
Ko'rsatmalarJaundice when acute viral hepatitis is suspected, Dark (tea-colored) urine or pale, acholic stools, Loss of appetite (anorexia), Marked fatigue, Nausea and vomiting, Abdominal pain, Fever, Arthralgia (joint pain), Cholestatic hepatitis presentation with malaise and fever, Unexplained elevations in total and direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or gamma-glutamyltransferase (GGT), Post-exposure assessment after contact with a person who has hepatitis A, regardless of symptoms

Natija og'ishlarining mumkin sabablari

Oshgan daraja

  • autoimmune disease
  • hiv infection

Namunangiz talablari

NamunangizZardob
ContainerOltin/yo'lbars qopqoqli probirka (SST, gel ajratgich)
Hajm1 mL (min 0.4 mL)
Saqlash tayyorlikXona harorati, Sovutilgan, Muzlatilgan

References

Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020 Jul 3;69(5):1-38. PubMed 32614811.

Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. PubMed 26042815.

Chernecky & Berger: Laboratory Tests and Diagnostic Procedures, 5th ed.

Ferri: Ferri's Clinical Advisor 2009, 1st ed.

Fischbach, Frances Talaska: Manual of Laboratory & Diagnostic Tests, 7th Edition.

Keogh: Nursing laboratory and diagnostic tests (2011).

Moisio: Understanding Laboratory and Diagnostic Tests (1998).